文献速递临床试验与 GCP流行病学与生物统计

多药房老年患者入住市级住院急性护理单元的药物审查跨医疗服务层级合作(COOP II研究):随机对照试验研究方案

Cooperation across healthcare service levels for medication reviews in older people with polypharmacy admitted to a municipal in-patient acute care unit (The COOP II Study): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2024-09-13

该研究为随机、单盲、对照优效性试验,纳入入住市级住院急性护理单元、年龄≥70岁且存在多药房问题的患者,比较由老年科医师督导、并与全科医师协作进行的临床药物审查联合常规照护与仅常规照护对健康相关生活质量及临床结局的影响,随访16周,同时评估干预的碳足迹。

要点

  • 纳入市级住院急性护理单元≥70岁多药房患者,随机分为干预组与常规照护组。
  • 干预为市级住院急性护理单元医师在老年科医师督导下进行结构化个体化药物审查,并与全科医师电话会议联合审查。
  • 主要结局为15D量表测量的健康相关生活质量,随访16周,同时评估干预碳足迹。

核心结论

  • 研究旨在评估市级住院急性护理单元内由老年科医师督导、与全科医师协作的临床药物审查对多药房老年患者健康相关生活质量及临床结局的潜在临床获益。
  • 研究结果可能为优化同类市级医疗环境中的患者照护提供有价值的信息。

研究设计与样本

  • 随机、单盲、对照优效性试验,随访16周,纳入市级住院急性护理单元中年龄≥70岁且存在多药房问题的患者。
  • 参与者随机分配至对照组(接受市级住院急性护理单元常规照护)或干预组(在常规照护基础上额外接受超出常规照护范围的临床药物审查)。
  • 药物审查采用结构化但个体化的框架评估用药适宜性,医师接受老年科医师督导;临床药物审查后,市级住院急性护理单元医师安排与参与者全科医师的电话会议,联合评估形成共同药物审查。
  • 研究于2023年8月30日在ClinicalTrials.gov前瞻性注册,标识符NCT06020391。

关键数值与推荐

  • 主要结局为15D量表测量的健康相关生活质量。
  • 次要结局包括躯体与认知功能、口腔健康、跌倒、入住医疗机构及死亡率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Polypharmacy and inappropriate drug use are associated with adverse health outcomes in older people. Collaborative interventions between geriatricians and general practitioners have demonstrated effectiveness in improving clinical outcomes for complex medication regimens in home-dwelling patients. Since 2012, Norwegian municipalities have established municipal in-patient acute care (MipAC) units, designed to contribute towards reducing the number of hospital admissions. These units predominantly serve older people who typically benefit from multidisciplinary approaches. The primary objective of this study is to evaluate the effect of cooperative medication reviews conducted by MipAC physicians, supervised by geriatricians, and in collaboration with general practitioners, on health-related quality of life and clinical outcomes in MipAC patients ≥ 70 years with polypharmacy. Additionally, the study aims to assess the carbon footprint of the intervention. METHODS: This is a randomized, single-blind, controlled superiority trial with 16 weeks follow-up. Participants will be randomly assigned to either the control group, receiving usual care at the MipAC unit, or to the intervention group which in addition receive clinical medication reviews that go beyond what is considered usual care. The medication reviews will evaluate medication appropriateness using a structured but individualized framework, and the physicians will receive supervision from geriatricians. Following the clinical medication reviews, the MipAC physicians will arrange telephone meetings with the participants' general practitioners to combine their assessments in a joint medication review. The primary outcome is health-related quality of life as measured by the 15D instrument. Secondary outcomes include physical and cognitive functioning, oral health, falls, admissions to healthcare facilities, and mortality. DISCUSSION: This study aims to identify potential clinical benefits of collaborative, clinical medication reviews within community-level MipAC units for older patients with polypharmacy. The results may offer valuable insights into optimizing patient care in comparable municipal healthcare settings. TRIAL REGISTRATION: The study was registered prospectively on ClinicalTrials.gov 30.08.2023 with identifier NCT06020391.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Santervas LR, Wyller TB, Skovlund E, et al. Cooperation across healthcare service levels for medication reviews in older people with polypharmacy admitted to a municipal in-patient acute care unit (The COOP II Study): study protocol for a randomized controlled trial. Trials. 2024. PMID: 39272164. doi:10.1186/s13063-024-08442-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。